Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Walgreens failed to disclose significant issues regarding regulatory compliance and unlawful conduct related to prescription medication, which led to misleading public statements and potential damages for investors [4]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering substantial amounts for investors [5]. - Investors are informed that no class has been certified yet, meaning they are not represented unless they retain counsel, and they can choose to remain absent from the class [7].

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/? id=137118&from ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Walgreens Boots Alliance (WBA) despite an increase in revenues, with actual results being crucial for stock price movement [1][3]. Earnings Expectations - The expected quarterly earnings per share (EPS) for Walgreens is $0.53, reflecting a year-over-year decrease of 55.8% [3]. - Revenues are projected to reach $37.92 billion, which is a 2.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.82% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - A positive Earnings ESP of +9.39% suggests that analysts are optimistic about Walgreens' earnings prospects [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Walgreens currently holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Walgreens exceeded the expected EPS of $0.37 by delivering $0.51, resulting in a surprise of +37.84% [12]. - Over the past four quarters, Walgreens has beaten consensus EPS estimates three times [13]. Conclusion - While Walgreens is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [16].

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Walgreens made false statements regarding its commitment to regulatory compliance while continuing to violate federal laws related to prescription medication [2]. - It is alleged that the company's unlawful conduct posed a risk of increased regulatory scrutiny, civil liability, and reputational damage [2]. - The revenues from prescription medication sales were deemed unsustainable due to their reliance on unlawful practices, rendering Walgreens' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/?id=136057&from= ...

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Walgreens made false statements and concealed ongoing violations of federal law regarding prescription medication dispensation and reimbursement [2]. - It is alleged that Walgreens' conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [2]. - The complaint asserts that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful practices, rendering public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing a class action lawsuit due to allegations of false statements and regulatory violations during the Class Period from April 2, 2020, to January 16, 2025 [1][3]. Group 1: Legal Allegations - The lawsuit claims that Walgreens violated federal laws regarding prescription medication dispensation and reimbursement, despite its stated commitment to regulatory compliance [3]. - It is alleged that these violations led to increased regulatory scrutiny, civil liability, and reputational harm for Walgreens [3]. - The lawsuit further asserts that Walgreens' prescription medication revenues were unsustainable, as they were partially derived from unlawful practices [4]. Group 2: Regulatory Actions and Impact - On January 17, 2025, the U.S. Department of Justice filed a civil complaint against Walgreens for dispensing millions of unlawful prescriptions in violation of the Controlled Substances Act and seeking reimbursement from federal health care programs in violation of the False Claims Act [5]. - Following the announcement of the DOJ complaint, Walgreens' stock price experienced a decline of more than 12% over two trading sessions [5].

Walgreens Boots Alliance TodayWBAWalgreens Boots Alliance$11.28 -0.11 (-0.97%) 52-Week Range$8.08▼$22.05Dividend Yield8.87%Price Target$11.54Add to WatchlistTroubled pharmacy chain Walgreens Boots Alliance Inc. NASDAQ: WBA has been a spectacular disappointment since completing its merging in 2014. Shares rose to a high of $97.14 following the union but had since fallen % to a low of $8.11 on November 21. 2024. The retail/wholesale sector giant’s attempt to grow into an integrated healthcare provider as the ...

Group 1 - Walgreens Boots Alliance announced a deal to go private, which was revealed after the market closed on March 6th [1] - The news generated significant interest among shareholders, indicating a potential shift in the company's operational strategy [1] Group 2 - The focus of Crude Value Insights is on cash flow and companies in the oil and natural gas sector, highlighting value and growth prospects [2] - Subscribers benefit from a stock model account, cash flow analyses of exploration and production firms, and live discussions about the sector [2]

Core Insights - Monteverde & Associates PC has successfully recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm is currently investigating Walgreens Boots Alliance, Inc. regarding its proposed merger with Sycamore Partners, where WBA shareholders are set to receive $11.45 and a non-transferable right to receive up to $3.00 in cash per share [1] Company Overview - Monteverde & Associates PC is headquartered in the Empire State Building, New York City, and operates as a national class action securities firm with a strong track record in litigation [2][3] - The firm emphasizes that no company, director, or officer is above the law, and it offers free consultations for shareholders with concerns [3] Legal Context - The firm is involved in class action lawsuits and has a history of recovering funds for shareholders, including cases that have reached the U.S. Supreme Court [2][4] - Shareholders of Walgreens Boots Alliance are encouraged to seek additional information regarding their rights and the ongoing investigation [3]